Summary & Overview
HCPCS Q9997: Ustekinumab-ttwe (Pyzchiva) Intravenous Injection, 1 mg
HCPCS Level II code Q9997 designates the intravenous injection of ustekinumab-ttwe (Pyzchiva), billed per 1 mg. This code identifies administration of a biologic monoclonal antibody therapy through an IV route, which is centrally relevant for specialty infusion providers, hospitals, and payers managing high-cost biologic therapies. Nationally, accurate coding of newer biosimilars and follow-on biologics affects utilization tracking, prior authorization workflows, and payment adjudication.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the service captured by Q9997, typical sites of service for administration, and the clinical context for an intravenous biologic injection. The publication summarizes coding specifics, common modifiers used in practice (listed separately), and outlines benchmarking and policy considerations that influence coverage and billing for high-cost injectable biologics. Where input data is missing, this report notes the absence rather than infer specifics. The content is intended for billing managers, reimbursement analysts, clinical coders, and policy teams seeking a clear, national-level reference for HCPCS Level II code Q9997.
Billing Code Overview
HCPCS Level II code Q9997 represents an intravenous injection of ustekinumab-ttwe (Pyzchiva), billed per 1 mg. The service is a biologic medication administration delivered intravenously and is typically provided in an infusion center, hospital outpatient department, or other clinical infusion setting. Service details beyond the code description are not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with moderate-to-severe Crohn disease or ulcerative colitis who requires intravenous induction dosing of ustekinumab-ttwe (Q9997) prior to subcutaneous maintenance. The patient presents to an outpatient infusion center or hospital outpatient department for a single intravenous administration calculated by weight (documented as 1 mg units billed via Q9997). The clinical workflow includes verification of prescription and weight-based dose, pre-infusion nursing assessment (vital signs, allergy check, review of concurrent medications and tuberculosis screening status), insertion of peripheral IV access, administration of the reconstituted biologic per manufacturer guidance, monitoring for infusion reactions during and for at least 30–60 minutes post-infusion, documentation of lot number and expiration, and billing of the appropriate HCPCS J- or Q-code for the amount administered along with facility and administration services. Typical site of service is an outpatient infusion center, hospital outpatient department, or specialty infusion clinic. Common patient modifiers applied to claims reflect bilateral procedures, unusual services, or patient status events as clinically appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Reserved/Not used in standard CMS modifier lists | Data not available in the input. |